the effects of Scaphoid and Hamate mobilization in patients with carpal tunnel syndrome

Study of the effects of Scaphoid and Hamate mobilization in patients with mild to moderate carpal tunnel syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015120125317N1

Enrollment

Registered

2016-01-11

Start date

2015-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carpal Tunnel Syndrome. Carpal Tunnel Syndrome

Interventions

Intervention 1: Intervention Group: Mobilization of Scaphoid and Hamate and Splint. Intervention 2: Control Group: Splint.

Treatment - Other

Intervention Group: Mobilization of Scaphoid and Hamate and Splint

Control Group: Splint

Eligibility

Sex/Gender

Female

Age

37 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: patient with mild and moderate CTS confirmed by the presence of 1 or more of the following standard electrophysiological criteria:1- prolonged distal motor latency (DML) (abnormal =4.2 ms)of Median nerve and 2) prolonged antidromic distal sensory latency (DSL) to the third digit (abnormal >3.6 ms. Exclusion criteria:Pregnancy; Severe degree CTS; Background metabolic diseases such as: Diabetes mellitus; Hypothyroidism; Rheumatoid arthritis; Previous history of Corticosteroid injection in Carpal Tunnel; Severe atrophy of Thener muscles; cervical radiculopathy or significant polyneuropathy; Unwillingness to participate in the present study;

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 0, 8 weeks after treatment. Method of measurement: Visual Analog Scale, that is from 0-10 and zero (0) means that you did not have any pain and ten (10) means that you had the worst pain imaginable.;Symptome Severity(pain and paresthesia). Timepoint: 0, 8 weeks after treatment. Method of measurement: Bostone/levine Symptome Severity Scale Questionnaire.;Functional Status. Timepoint: 0, 8 weeks after treatment. Method of measurement: Bostone/levine Functional Status Scale Questionnare.;Distal Sensory Peak Latency(SNAP) of median nerve. Timepoint: 0, 8 weeks after treatment. Method of measurement: EDX Indexes.;Distal Motor Onset Latency(CMAP) of median nerve. Timepoint: 0, 8 weeks after treatment. Method of measurement: EDX indexes.	—

Measure

Time frame

Pain. Timepoint: 0, 8 weeks after treatment. Method of measurement: Visual Analog Scale, that is from 0-10 and zero (0) means that you did not have any pain and ten (10) means that you had the worst pain imaginable.;Symptome Severity(pain and paresthesia). Timepoint: 0, 8 weeks after treatment. Method of measurement: Bostone/levine Symptome Severity Scale Questionnaire.;Functional Status. Timepoint: 0, 8 weeks after treatment. Method of measurement: Bostone/levine Functional Status Scale Questionnare.;Distal Sensory Peak Latency(SNAP) of median nerve. Timepoint: 0, 8 weeks after treatment. Method of measurement: EDX Indexes.;Distal Motor Onset Latency(CMAP) of median nerve. Timepoint: 0, 8 weeks after treatment. Method of measurement: EDX indexes.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVida Dinarvand

University of Social Welfare and Rehabilitations Sciences

vi.dinarvand@uswr.ac.ir+98 21 2235 3581

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026